Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).

NCT ID: NCT01967706

Last Updated: 2020-03-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 Menthol (mTHS), a candidate Modified Risk Tobacco Product, compared to the PK profiles from a single use of a menthol cigarette (mCC) and from a single use of nicotine replacement therapy gum (NRT).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mTHS then mCC

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mTHS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mCC).

Group Type ACTIVE_COMPARATOR

mTHS

Intervention Type OTHER

Single use of Tobacco Heating System 2.2 Menthol (mTHS)

mCC

Intervention Type OTHER

Single use of subject's own menthol cigarette (mCC)

mCC then mTHS

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mCC)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mTHS).

Group Type ACTIVE_COMPARATOR

mTHS

Intervention Type OTHER

Single use of Tobacco Heating System 2.2 Menthol (mTHS)

mCC

Intervention Type OTHER

Single use of subject's own menthol cigarette (mCC)

mTHS then NRT

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single product use of mTHS)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single administration of NRT)

Group Type ACTIVE_COMPARATOR

mTHS

Intervention Type OTHER

Single use of Tobacco Heating System 2.2 Menthol (mTHS)

NRT

Intervention Type OTHER

Single administration of 2 mg gum (Nicorette® 2mg)

NRT then mTHS

Each subject will follow the below study design:

* Day 0 = Wash-out (1 day)
* Day 1 = 1st intervention (single administration of NRT)
* Day 2 = wash-out
* Day 3 = 2nd intervention (single product use of mTHS).

Group Type ACTIVE_COMPARATOR

mTHS

Intervention Type OTHER

Single use of Tobacco Heating System 2.2 Menthol (mTHS)

NRT

Intervention Type OTHER

Single administration of 2 mg gum (Nicorette® 2mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mTHS

Single use of Tobacco Heating System 2.2 Menthol (mTHS)

Intervention Type OTHER

mCC

Single use of subject's own menthol cigarette (mCC)

Intervention Type OTHER

NRT

Single administration of 2 mg gum (Nicorette® 2mg)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is Japanese.
* Smoking, healthy subject as judged by the Investigator.
* Subject has smoked at least 10 commercially available mCCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.

Exclusion Criteria

* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
* Subject has received medication within 14 days or within 5 half-lives of a medication (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
Minimum Eligible Age

23 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Philip Morris Products S.A.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christelle Haziza, PhD

Role: STUDY_CHAIR

Philip Morris Products S.A.

Fumimasa Nobuoka, MD

Role: PRINCIPAL_INVESTIGATOR

Ageo Medical Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ageo Medical Clinic, 3133 Haraichi, Ageo-shi

Saitama, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZRHM-PK-05-JP

Identifier Type: OTHER

Identifier Source: secondary_id

ZRHM-PK-05-JP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.